Tarsus Pharmaceuticals (NASDAQ:TARS) Earns Buy Rating from HC Wainwright

Tarsus Pharmaceuticals (NASDAQ:TARS)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $73.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 67.62% from the stock’s current price. HC Wainwright also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2028 earnings at $5.10 EPS and FY2029 earnings at $6.29 EPS.

A number of other equities analysts have also issued reports on the company. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday. The Goldman Sachs Group upped their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Friday, November 15th. Finally, Barclays upped their price target on Tarsus Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Monday, January 27th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $61.33.

Tarsus Pharmaceuticals Stock Up 2.3 %

NASDAQ TARS opened at $43.55 on Wednesday. The business has a 50 day moving average price of $51.14 and a two-hundred day moving average price of $43.00. Tarsus Pharmaceuticals has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The stock has a market cap of $1.66 billion, a PE ratio of -11.43 and a beta of 1.01. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Tarsus Pharmaceuticals (NASDAQ:TARS) last announced its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million for the quarter, compared to analyst estimates of $58.80 million. As a group, sell-side analysts predict that Tarsus Pharmaceuticals will post -3.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Crowley Wealth Management Inc. bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $25,000. GF Fund Management CO. LTD. bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $44,000. R Squared Ltd bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $53,000. FMR LLC grew its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock worth $166,000 after buying an additional 3,537 shares during the last quarter. Finally, Quarry LP bought a new position in Tarsus Pharmaceuticals during the 4th quarter worth $166,000. 90.01% of the stock is owned by institutional investors and hedge funds.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.